Description and Intended Use
Amnio-Maxx® is a family of amnion patch allografts intended for use as a protective barrier from the surrounding environment for acute and chronic wounds. Examples include diabetic ulcers, venous ulcers, surgical wounds (post-Mohs surgery, post-laser surgery, podiatric wounds, wound dehiscence), chronic vascular ulcers, pressure and non-pressure ulcers, tunneled/undermined wounds, trauma wounds (partial thickness burns, abrasions, skin tears, lacerations), and draining wounds. Amnio-Maxx Dual Layer Amnion Patch may be applied from the onset of the wound and for the duration of the wound, weekly or at the discretion of the health care practitioner.
Clinically Relevant Features
DUAL-LAYER
Dual-layer design is intended to provide increased thickness and durability.
DESIGNED TO SUPPORT EASE OF USE
Increased thickness may support improved handling characteristics during surgical procedures and wound management.
SURGICAL BARRIER
Designed for use as a protective covering and barrier in surgical procedures and wound management.
DESIGNED TO SUPPORT EASE OF PLACEMENT
Dual-layer configuration is designed to support flexible placement without strict orientation requirements.
Ordering Information
- Code Description
- AMN-22 Amnio-Maxx® 2cm x 2cm
- AMN-24 Amnio-Maxx® 2cm X 4cm
- AMN-44 Amnio-Maxx® 4cm X 4cm
- AMN-48 Amnio-Maxx® 4cm X 8cm
REFERENCES
1. Spoerl, E.; Wollensak, G.; Reber, F.; Pillunat, L. Cross-linking of human amniotic membrane by glutaraldehyde. {\em Ophthalmic Res.} {2004}, {\em 36}, 71–77. https://doi.org/10.1159/000075648 Reference discusses the physical and structural properties of amniotic membrane following cross-linking.
2. Niknejad, H.; Peirovi, H.; Jorjani, M.; Ahmadiani, A.; Ghanavi, J.; Seifalian, A.M. Properties of the amniotic membrane for potential use in tissue engineering. {\em Eur. Cell Mater.} {2008}, {\em 15}, 88–99. https://doi.org/10.22203/eCM.v015a07
3. Mamede, A.C.; Carvalho, M.J.; Abrantes, A.M.; Laranjo, M.; Maia, C.J.; Botelho, M.F. Amniotic membrane: From structure and functions to clinical applications. {\em Cell Tissue Res.} {2012}, {\em 349}, 447–458. https://doi.org/10.1007/s00441-012-1424-6* *Published literature describes general structural and compositional characteristics of human amniotic membrane.
2. Niknejad, H.; Peirovi, H.; Jorjani, M.; Ahmadiani, A.; Ghanavi, J.; Seifalian, A.M. Properties of the amniotic membrane for potential use in tissue engineering. {\em Eur. Cell Mater.} {2008}, {\em 15}, 88–99. https://doi.org/10.22203/eCM.v015a07
3. Mamede, A.C.; Carvalho, M.J.; Abrantes, A.M.; Laranjo, M.; Maia, C.J.; Botelho, M.F. Amniotic membrane: From structure and functions to clinical applications. {\em Cell Tissue Res.} {2012}, {\em 349}, 447–458. https://doi.org/10.1007/s00441-012-1424-6* *Published literature describes general structural and compositional characteristics of human amniotic membrane.
*A prospective clinical study evaluating the effect of Amnio-Maxx® on chronic diabetic foot ulcers is currently ongoing. Study Title: Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. ClinicalTrials.gov Identifier: NCT07209475
Results are pending
Results are pending